Y 26763

structure given in first source; an active metabolite of Y 27152

Also Known As:

(+)-(3S,4R)-(N-acetyl-N-hydroxy)amino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol; Y-26763; Acetamide, N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-hydroxy-, (3S-trans)-

Networked: 7 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Y 26763: 7
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Y 26763: 7

Experts

1.	Aikawa, M: 1 article (06/2000)
2.	Deguchi, Y: 1 article (06/2000)
3.	Handa, S: 1 article (06/2000)
4.	Tanabe, T: 1 article (06/2000)
5.	Yoshioka, K: 1 article (06/2000)

Related Diseases

1.	Ischemia 01/01/1997 - "Y-26763 significantly inhibited the increase in extracellular glutamate concentration at 50 and 60 min of ischemia with a significant reduction of mean arterial blood pressure. " 12/19/1996 - "This investigation was undertaken to determine the possible protection against ischemia afforded by Y-26763, [(-)-(3S,4R)-4-(N- acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran- 3- ol], which has K+ channel-opening properties, in isolated rat hearts under working conditions. " 06/01/2000 - "The purpose of the study was to determine whether a new KATP channel opener, Y 26763 (Y), can influence the electrophysiological properties in the ischemic myocardium as well as to determine whether the blunting effect of the alpha 1-adrenoceptor antagonist bunazosin (BN) on an ischemia-induced shortening of repolarization time can be related to the KATP channel activity. "
2.	Reperfusion Injury 04/04/1997 - "Overall, these results indicate that Y-26763 protects the canine myocardium from reversible ischemia/reperfusion injury, probably through activation of myocardial KATP channels which appear to be involved in affording protection during the ischemic insult and not at the reperfusion." 12/19/1996 - "Y-26763 protects the working rat myocardium from ischemia/reperfusion injury through opening of KATP channels." 04/04/1997 - "The present study describes the protective effects of the ATP-sensitive K+ (KATP) channel opener Y-26763 ((-)-(3S,4R-4-(N-acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl -2H-1-benzopyran-3-ol), on a model of reversible ischemia/reperfusion injury ('stunned' myocardium). "
3.	Myocardial Stunning (Stunned Myocardium) 04/04/1997 - "The present study describes the protective effects of the ATP-sensitive K+ (KATP) channel opener Y-26763 ((-)-(3S,4R-4-(N-acetyl-N-hydroxyamino)-6-cyano-3,4-dihydro-2,2-dimethyl -2H-1-benzopyran-3-ol), on a model of reversible ischemia/reperfusion injury ('stunned' myocardium). "
4.	Infarction (Infarctions) 08/01/1997 - "Although Y-26763 lowered systemic blood pressure by 13 mmHg, the infarct volume assessed 3 days after the occlusion was significantly smaller in the Y-26763-treated group (n = 12, 71.2 +/- 22.0 mm3) than in the control group (n = 12, 94.7 +/- 20.4 mm3, P = 0.013). " 01/01/1997 - "These results suggest that Y-26763 inhibited presynaptic glutamate release through hyperpolarizing the membrane, but infarct volume was not reduced because of insufficient perfusion owing to its hypotensive effect."
5.	Acute Kidney Injury (Acute Renal Failure) 07/01/1997 - "Y-26763, a benzopyran derivative, is a newly developed ATp-sensitive K channel opener and has been reported to protect against ischemic acute renal failure (ARF). "

Related Drugs and Biologics

1.	Benzopyrans
2.	KATP Channels
3.	Adenosine Triphosphate (ATP)
4.	Glutamic Acid (Glutamate)
5.	bunazosin (Andante)
6.	Cilazapril
7.	Antihypertensive Agents (Antihypertensives)
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)